Statistics from Altmetric.com
Coronary artery disease remains the leading cause of death around the world, even during the COVID-19 pandemic, and it is therefore essential that we continue our quest to improve the prevention, diagnosis, management and outcome of coronary artery disease. Fifty years ago, in 1971, the first CT scan was performed on a machine invented by Sir Godfrey Hounsfield who, even in those early days, realised the potential of CT to assess the heart and coronary arteries.1 Technological advances mean that it is now possible to obtain extensive information on the presence, severity and characteristics of atherosclerotic plaque from coronary CT angiography (CCTA). In addition, it is also possible to use computational modelling to obtain an estimate of fractional flow reserve from static CCTA images (FFRCT). CCTA now plays a central role in the assessment and management of patients with symptoms of suspected coronary artery disease in both national and international guidelines. However, the role of FFRCT in clinical practice is less certain.
Nørgaard et al 2 present a meta-analysis of the prognostic information provided by FFRCT from a single vendor (HeartFlow) in 5460 patients from 5 observational studies and registries. Coronary artery disease was prevalent in the population, with 72% having at least one stenosis >50% on CCTA and 61% having a positive FFRCT of ≤0.80. Overall event rates were low, with myocardial infarction or all-cause mortality occurring in 0.6% of FFRCT negative patients and 1.4% of FFRCT positive patients. Patients with FFRCT ≤0.80 were threefold more likely to experience myocardial infarction, unplanned coronary revascularisation and major adverse cardiac events, although there was no demonstrable difference in all-cause mortality. In addition, lower FFR …
Contributors MCW wrote the original draft. MCW and DEN performed critical review and editing of the manuscript.
Funding MCW (FS/ICRF/20/26002) and DEN (CH/09/002, RG/16/10/32375, RE/18/5/34216) are supported by the British Heart Foundation. DEN is the recipient of a Wellcome Trust Senior Investigator Award (WT103782AIA). MCW is supported by The Chief Scientist Office of the Scottish Government Health and Social Care Directorates (PCL/17/04).
Competing interests DEN is the Principal Investigator and MCW is member of the steering committee of the SCOT-HEART trial. DEN and MCW have published research using the AutoPlaque software. MCW has received honoraria from Canon Medical Systems.
Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.
Provenance and peer review Commissioned; internally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.